Already a member? Become a member Register
PCSK9 Forum

rss LinkedIn News
rss LinkedIn Latest News Updates


Posted on 2 February 2021 | Posted in Evolocumab
Trial Early Treatment With Evolocumab in Patients With ST-elevation Myocardial Infarction (ExOTIC) Identifier: NCT04303377

Aim To investigate the effect of evolocumab in patients hospitalized with a diagnosis of ST-elevation myocardial infarction (STEMI)
Study design Randomized, parallel-group, open-label

All patients will receive standard of care, including high dose of statin ± ezetimibe. Evolocumab 140 mg every 2 weeks will be administered in the acute phase of STEMI.

The duration of the study is 6 months.

Patients 154 patients with chest pain or equivalent lasting > 20 minutes, with STEMI scheduled for primary PCI. Exclusion criteria included previous MI, percutaneous or surgical myocardial revascularization, ongoing treatment with any statin or ezetimibe, history of congestive heart failure, or cardiogenic shock at presentation.
Primary outcome Reduction in infarct size from baseline to 6 months
Key results Ongoing
Author conclusion  


Related content